Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03756285 · ClinicalTrials.gov registry record · Phase 2
Safety and Tolerability Study of AZD4831 in Patients With Heart Failure.
A Phase 2 study, sponsored by AstraZeneca.
- Terminated
- Registry status
- Phase 2
- Development phase
- 41
- Enrollment target
NCT03756285 is a Phase 2 study that was terminated before completion, run by AstraZeneca. The registered enrollment target is 41 participants.
The verdict
NCT03756285, a Phase 2 study, was terminated before completion, sponsored by AstraZeneca.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 41 participants
- Enrollment target
Study Summary
A randomized, double-blind, placebo-controlled, parallel group, multicentre study in patients with Heart Failure with preserved Ejection Fraction (HFpEF). The study will be conducted at approximately 15 sites in 5 countries. Approximately 96 patients will be randomized to AZD4831 or placebo (treatment duration 90 days).
Interventions
- DRUG Placebo
- DRUG AZD4831
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2018-12-11 |
| Est. Completion | 2020-05-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03756285
The ClinicalTrials.gov registry entry for NCT03756285 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03756285 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03756285 about?
NCT03756285 is a clinical study titled "Safety and Tolerability Study of AZD4831 in Patients With Heart Failure.". A randomized, double-blind, placebo-controlled, parallel group, multicentre study in patients with Heart Failure with preserved Ejection Fraction (HFpEF). The study will be conducted at approximately 15 sites in 5 countries. Approximately 96 patients will be randomized to AZD4831 or placebo (treatme...
What is the current status of trial NCT03756285?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 2018-12-11. Estimated completion is 2020-05-07.
What interventions are being tested in trial NCT03756285?
The interventions under investigation include: Placebo (DRUG), AZD4831 (DRUG).
Who is sponsoring clinical trial NCT03756285?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.